Literature DB >> 25877150

Application of Parallel Multiparametric Cell-Based FLIPR Detection Assays for the Identification of Modulators of the Muscarinic Acetylcholine Receptor 4 (M4).

Emery Smith1, Peter Chase1, Colleen M Niswender2, Thomas J Utley2, Douglas J Sheffler3, Meredith J Noetzel2, Atin Lamsal2, Michael R Wood2, P Jeffrey Conn2, Craig W Lindsley2, Franck Madoux1, Mary Acosta1, Louis Scampavia1, Timothy Spicer4, Peter Hodder5.   

Abstract

Muscarinic acetylcholine receptors (mAChRs) have long been viewed as viable targets for novel therapeutic agents for the treatment of Alzheimer's disease and other disorders involving impaired cognitive function. In an attempt to identify orthosteric and allosteric modulators of the muscarinic acetylcholine receptor M(4) (M(4)), we developed a homogenous, multiparametric, 1536-well assay to measure M(4) receptor agonism, positive allosteric modulation (PAM), and antagonism in a single well. This assay yielded a Z' of 0.85 ± 0.05 in the agonist, 0.72 ± 0.07 in PAM, and 0.80 ± 0.06 in the antagonist mode. Parallel screening of the M(1) and M(5) subtypes using the same multiparametric assay format revealed chemotypes that demonstrate selectivity and/or promiscuity between assays and modalities. This identified 503 M(4) selective primary agonists, 1450 PAMs, and 2389 antagonist hits. Concentration-response analysis identified 25 selective agonists, 4 PAMs, and 41 antagonists. This demonstrates the advantages of this approach to rapidly identify selective receptor modulators while efficiently removing assay artifacts and undesirable compounds.
© 2015 Society for Laboratory Automation and Screening.

Entities:  

Keywords:  GPCR; muscarinic; parallel screening; positive allosteric modulators

Mesh:

Substances:

Year:  2015        PMID: 25877150      PMCID: PMC4659430          DOI: 10.1177/1087057115581770

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN: 1087-0571


  24 in total

1.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.

Authors: 
Journal:  J Biomol Screen       Date:  1999

Review 2.  G-protein-coupled receptor oligomerization and its potential for drug discovery.

Authors:  Susan R George; Brian F O'Dowd; Samuel P Lee
Journal:  Nat Rev Drug Discov       Date:  2002-10       Impact factor: 84.694

3.  Selective and brain penetrant neuropeptide y y2 receptor antagonists discovered by whole-cell high-throughput screening.

Authors:  Shaun P Brothers; S Adrian Saldanha; Timothy P Spicer; Michael Cameron; Becky A Mercer; Peter Chase; Patricia McDonald; Claes Wahlestedt; Peter S Hodder
Journal:  Mol Pharmacol       Date:  2009-10-16       Impact factor: 4.436

Review 4.  Genetic variations and polymorphisms of G protein-coupled receptors: functional and therapeutic implications.

Authors:  B K Rana; T Shiina; P A Insel
Journal:  Annu Rev Pharmacol Toxicol       Date:  2001       Impact factor: 13.820

Review 5.  The 7 TM G-protein-coupled receptor target family.

Authors:  Edgar Jacoby; Rochdi Bouhelal; Marc Gerspacher; Klaus Seuwen
Journal:  ChemMedChem       Date:  2006-08       Impact factor: 3.466

Review 6.  Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders.

Authors:  P Jeffrey Conn; Carrie K Jones; Craig W Lindsley
Journal:  Trends Pharmacol Sci       Date:  2009-02-07       Impact factor: 14.819

Review 7.  Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders.

Authors:  P Jeffrey Conn; Arthur Christopoulos; Craig W Lindsley
Journal:  Nat Rev Drug Discov       Date:  2009-01       Impact factor: 84.694

8.  Discovery, synthesis and characterization of a highly muscarinic acetylcholine receptor (mAChR)-selective M5-orthosteric antagonist, VU0488130 (ML381): a novel molecular probe.

Authors:  Patrick R Gentry; Masaya Kokubo; Thomas M Bridges; Hyekyung P Cho; Emery Smith; Peter Chase; Peter S Hodder; Thomas J Utley; Anuruddha Rajapakse; Frank Byers; Colleen M Niswender; Ryan D Morrison; J Scott Daniels; Michael R Wood; P Jeffrey Conn; Craig W Lindsley
Journal:  ChemMedChem       Date:  2014-04-01       Impact factor: 3.466

Review 9.  Muscarinic acetylcholine receptors as CNS drug targets.

Authors:  Christopher J Langmead; Jeannette Watson; Charlie Reavill
Journal:  Pharmacol Ther       Date:  2007-12-20       Impact factor: 12.310

Review 10.  Anticholinergics for symptomatic management of Parkinson's disease.

Authors:  R Katzenschlager; C Sampaio; J Costa; A Lees
Journal:  Cochrane Database Syst Rev       Date:  2003
View more
  14 in total

1.  Optimization of M4 positive allosteric modulators (PAMs): The discovery of VU0476406, a non-human primate in vivo tool compound for translational pharmacology.

Authors:  Bruce J Melancon; Michael R Wood; Meredith J Noetzel; Kellie D Nance; Eileen M Engelberg; Changho Han; Atin Lamsal; Sichen Chang; Hyekyung P Cho; Frank W Byers; Michael Bubser; Carrie K Jones; Colleen M Niswender; Michael W Wood; Darren W Engers; Dedong Wu; Nicholas J Brandon; Mark E Duggan; P Jeffrey Conn; Thomas M Bridges; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2017-04-13       Impact factor: 2.823

2.  Discovery and SAR of a novel series of potent, CNS penetrant M4 PAMs based on a non-enolizable ketone core: Challenges in disposition.

Authors:  Michael R Wood; Meredith J Noetzel; James C Tarr; Alice L Rodriguez; Atin Lamsal; Sichen Chang; Jarrett J Foster; Emery Smith; Peter Chase; Peter S Hodder; Darren W Engers; Colleen M Niswender; Nicholas J Brandon; Michael W Wood; Mark E Duggan; P Jeffrey Conn; Thomas M Bridges; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2016-07-21       Impact factor: 2.823

3.  Discovery of a novel 2,4-dimethylquinoline-6-carboxamide M4 positive allosteric modulator (PAM) chemotype via scaffold hopping.

Authors:  Madeline F Long; Julie L Engers; Sichen Chang; Xiaoyan Zhan; Rebecca L Weiner; Vincent B Luscombe; Alice L Rodriguez; Hyekyung P Cho; Colleen M Niswender; Thomas M Bridges; P Jeffrey Conn; Darren W Engers; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2017-10-09       Impact factor: 2.823

4.  Challenges in the development of an M4 PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amides.

Authors:  James C Tarr; Michael R Wood; Meredith J Noetzel; Jeanette L Bertron; Rebecca L Weiner; Alice L Rodriguez; Atin Lamsal; Frank W Byers; Sichen Chang; Hyekyung P Cho; Carrie K Jones; Colleen M Niswender; Michael W Wood; Nicholas J Brandon; Mark E Duggan; P Jeffrey Conn; Thomas M Bridges; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2017-05-06       Impact factor: 2.823

5.  Challenges in the development of an M4 PAM in vivo tool compound: The discovery of VU0467154 and unexpected DMPK profiles of close analogs.

Authors:  Michael R Wood; Meredith J Noetzel; Michael S Poslusney; Bruce J Melancon; James C Tarr; Atin Lamsal; Sichen Chang; Vincent B Luscombe; Rebecca L Weiner; Hyekyung P Cho; Michael Bubser; Carrie K Jones; Colleen M Niswender; Michael W Wood; Darren W Engers; Nicholas J Brandon; Mark E Duggan; P Jeffrey Conn; Thomas M Bridges; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2016-11-30       Impact factor: 2.823

6.  Discovery of structurally distinct tricyclic M4 positive allosteric modulator (PAM) chemotypes - Part 2.

Authors:  Madeline F Long; Rory A Capstick; Paul K Spearing; Julie L Engers; Alison R Gregro; Sean R Bollinger; Sichen Chang; Vincent B Luscombe; Alice L Rodriguez; Hyekyung P Cho; Colleen M Niswender; Thomas M Bridges; P Jeffrey Conn; Craig W Lindsley; Darren W Engers; Kayla J Temple
Journal:  Bioorg Med Chem Lett       Date:  2021-10-26       Impact factor: 2.823

7.  Discovery of a novel, CNS penetrant M4 PAM chemotype based on a 6-fluoro-4-(piperidin-1-yl)quinoline-3-carbonitrile core.

Authors:  Blake R Bewley; Paul K Spearing; Rebecca L Weiner; Vincent B Luscombe; Xiaoyan Zhan; Sichen Chang; Hyekyung P Cho; Alice L Rodriguez; Colleen M Niswender; P Jeffrey Conn; Thomas M Bridges; Darren W Engers; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2017-08-20       Impact factor: 2.823

8.  Discovery and optimization of a novel series of highly CNS penetrant M4 PAMs based on a 5,6-dimethyl-4-(piperidin-1-yl)thieno[2,3-d]pyrimidine core.

Authors:  Michael R Wood; Meredith J Noetzel; Julie L Engers; Katrina A Bollinger; Bruce J Melancon; James C Tarr; Changho Han; Mary West; Alison R Gregro; Atin Lamsal; Sichen Chang; Sonia Ajmera; Emery Smith; Peter Chase; Peter S Hodder; Michael Bubser; Carrie K Jones; Corey R Hopkins; Kyle A Emmitte; Colleen M Niswender; Michael W Wood; Mark E Duggan; P Jeffrey Conn; Thomas M Bridges; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2016-05-05       Impact factor: 2.823

9.  Identification of Potential Pharmacoperones Capable of Rescuing the Functionality of Misfolded Vasopressin 2 Receptor Involved in Nephrogenic Diabetes Insipidus.

Authors:  Emery Smith; Jo Ann Janovick; Thomas D Bannister; Justin Shumate; Louis Scampavia; P Michael Conn; Timothy P Spicer
Journal:  J Biomol Screen       Date:  2016-06-08

Review 10.  Advances in G protein-coupled receptor high-throughput screening.

Authors:  Emily A Yasi; Nicholas S Kruyer; Pamela Peralta-Yahya
Journal:  Curr Opin Biotechnol       Date:  2020-07-10       Impact factor: 9.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.